Oxolife is a small-sized clinical-stage biotech company, founded in 2013 by Ignasi Canals and Agnès Arbat, focused and committed to female fertility improvement.
A solid project
It is estimated that infertility affects 75.8 million women worldwide. Each year, more than 3 million assisted reproduction procedures are performed, including in vitro fertilisation (IVF). Despite the treatments that exist to induce ovulation and modern techniques to mature and fertilise oocytes, more than half of all ART cycles end in disappointment due to Implantation failure or early pregnancy loss, the main causes of failure in female fertility treatments. These remain unsolved problems in reproductive medicine.
There is no pharmacological intervention in the market that enhances the implantation process through a direct effect on the endometrium. Oxolife’s innovation is a first-in-class oral drug for the treatment of infertile women, named OXO-001, that increases embryo implantation success and pregnancy rates.
Currently, there is no specific drug commercially available for Polycystic ovary syndrome (PCOS),the most common endocrine disorder that affects 10-15% of childbearing age women. So far, the drugs that have been used to treat this syndrome have been directed at the symptoms but not at the syndrome itself.
At Oxolife, we are also studying the use of our drug OXO-001 to treat infertility associated with PCOS, where the pregnancy success rate is still very low despite the existing treatments
Oxolife’s mission is to bring to market the first treatment that improves embryo implantation.
Our vision is to improve women’s fertility worldwide, simplifying the process that infertile women and couples go through. At the same time, we are committed to provide the first implantation treatment available to the scientific community and to improve the understanding of implantation processes.
We are guided by values of excellence, rigor, perseverance, determination, honesty, and the empowerment of people.